Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis group B isolates in a serum bactericidal antibody assay

Clinical and Vaccine Immunology

Volumn 14, Issue 11, 2007, Pages 1451-1457

  Findlow, Jamie ^a   Holland, Ann ^a   Andrews, Nick ^b   Weynants, Vincent ^c   Sotolongo, Franklin ^d   Balmer, Paul ^a   Poolman, Jan ^c   Borrow, Ray ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d FINLAY INSTITUTE   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; LIPOOLIGOSACCHARIDE; MEMBRANE PROTEIN; MENINGOCOCCUS VACCINE; OPC PROTEIN; PORB PROTEIN; PORIN A; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOASSAY; MEMBRANE VESICLE; MENINGITIS; NEISSERIA MENINGITIDIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIALYLATION;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; SERUM BACTERICIDAL TEST;

EID: 37349020019     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00195-07     Document Type: Article

References (29)

1. Aase, A., T. K. Herstad, S. Sandbu, B. Feiring, L. M. Naess, P. Oster, E. Rosenqvist, T. E. Michaelsen, O. Heiland, and H. Nokleby. 2005. Opsonophagocytic activity and IgG responses against live meningococci after vaccination with a combination of two serogroup B OMV vaccines, MenBvac and MeNZB, abstr. P52. Eighth Meet. Eur. Monitoring Group Meningococci, Dublin, Ireland.
2. Borrow, R., I. S. Aaberge, G. F. Santos, T. L. Eudey, P. Oster, A. Glennie, J. Findlow, E. A. Høiby, E. Rosenqvist, P. Balmer, and D. Martin. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol. 12:970-976.
3. Borrow, R., G. M. Carlone, N. Rosenstein, M. Blake, I. Feavers, D. Martin, W. Zollinger, J. Robbins, I. S. Aaberge, D. M. Granof, E. Miller, B. Plikaytis, L. van Alphen, J. Poolman, R. Rappuoli, L. Danzig, J. Hackell, B. Danve, M. Caulfield, S. Lambert, and D. Stephens. 2006. Neisseria meningitidis group B correlates of protection and assay standardization - international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 24:5093-5107.
4. Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, W. Silva, E. Moran, W. Hankins, J. Gilly, P. Mays, and The Chilean National Committee for Meningococcal Disease. 1995. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 13:821-829.
5. Boutriau, D., J. Poolman, R. Borrow, J. Findlow, J. Diez-Domingo, J. Puig-Barbera, J. M. Baldo, V. Planelles, A. Jubert, J. Colomer, A. Gil, K. Levie, A.-D. Kervyn, V. Weynants, F. Dominguez, R. Barbera, and F. Sotolongo. 2007. Immunogenicity and safety of a bivalent (B:4:P1.19,15 and B:4:P1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin. Vaccine Immunol. 14:65-73.
6. Findlow, J., A. Lowe, S. Deane, P. Balmer, G. van den Dobbelsteen, M. Dawson, N. Andrews, and R. Borrow. 2005. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children. Vaccine 23:2623-2627.
7. Findlow, J., S. Taylor, A. Aase, R. Horton, R. Heyderman, J. Southern, N. Andrews, R. Barchha, E. Harrison, A. Lowe, E. Boxer, C. Heaton, P. Balmer, E. Kaczmarski, P. Oster, A. Gorringe, R. Borrow, and E. Miller. 2006. Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect. Immun. 74:4557-4565.
8. Finne, J., M. Leinonen, and P. H. Mäkelä. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet ii:355-357.
9. Fredriksen, J. H., E. Rosenqvist, E. Wedege, K. Bryn, G. Bjune, L. O. Froholm, A. K. Lindbak, B. Mogster, E. Namork, U. Rye, G. Stabbertorp, R. Winsnes, A. Aase, and O. Closs. 1991. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14:67-80.
10. Giuliani, M. M., J. Adu-Bobie, M. Comanducci, B. Arico, S. Savino, L. Santini, B. Brunelli, S. Bambini, A. Biolchi, B. Capecchi, E. Cartocci, L. Ciucchi, F. Di Marcello, F. Ferlicca, B. Galli, E. Luzzi, V. Masignani, D. Semite, D. Veggi, M. Contorni, M. Morandi, A. Bartalesi, V. Cinotti, D. Mannucci, F. Titta, E. Ovidi, J. A. Welsch, D. Granoff, R. Rappuoli, and M. Pizza. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. USA 103:10834-10839.
11. Gray, S. J., C. L. Trotter, M. E. Ramsay, M. Guiver, A. J. Fox, R. Borrow, R. H. Mallard, and E. B. Kaczmarski. 2006. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/4: contribution and experiences of the Meningococcal Reference Unit. J. Med. Microbiol. 55:887-896.
12. Hoist, J., B. Feiring, J. E. Fuglesang, E. A. Høiby, H. Nokleby, I. S. Aaberge, and E. Rosenqvist. 2003. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 21:734-737.
13. Martin, D., N. Ruijne, L. McCallum, J. O'Hallahan, and P. Oster. 2006. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin. Vaccine Immunol. 13:486-491.
14. Maslanka, S. E., L. L. Gheesling, D. E. Libutti, K. B. Donaldson, H. S. Harakeh, J. K. Dykes, F. F. Arhin, S. J. Devi, C. E. Frasch, J. C. Huang, P. Kriz-Kuzemenska, R. D. Lemmon, M. Lorange, C. C. Petters, S. Quataert, J. Y. Tai, and G. M. Carlone. 1997. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin. Diagn. Lab. Immunol. 4:156-167.
15. Milagres, L. G., M. C. Gorla, M. C. Rebelo, and D. E. Barroso. 2000. Bactericidal antibody responses to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunisation with an outer membrane protein vaccine. FEMS Immunol. Med. Microbiol. 28:319-327.
16. Milagres, L. G., M. C. Gorla, C. T. Sacchi, and M. M. Rodrigues. 1998. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine. Infect. Immun. 66:4755-4761.
17. Moran, E. E., B. L. Brandt, and W. D. Zollinger. 1994. Expression of the L8 lipoporysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity. Infect. Immun. 62:5290-5295.
18. Oster, P., D. Lennon, J. O'Hallahan, K. Mulholland, S. Reid, and D. Martin. 2005. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23:2191-2196.
19. Rosenqvist, E., E. Høiby, E. Wedege, K. Bryn, J. Kolberg, A. Klem, E. Ronnild, G. Bjune, and H. Nokleby. 1995. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group meningococcal vaccine. Infect. Immun. 63:4642-4652.
20. Scholten, R. J., B. Kuipers, H. A. Valkenburg, J. Dankert, W. D. Zollinger, and J. T. Poolman. 1994. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J. Med. Microbiol. 41:236-243.
21. Sierra, G. V. C., H. C. Campa, N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:195-210.
22. Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L. L. Gheesling, G. M. Carlone, E. A. Heiby, J. Holst, H. Nokleby, E. Rosenqvist, G. Sierra, C. Campa, F. Sotolongo, J. Vega, J. Garcia, P. Herrera, J. T. Poolman, and B. A. Perkins. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomised controlled trial in Chile. JAMA 281:1520-1527.
23. Uria, J. M., C. M. Tang, and J. Vazquez. 2005. Characterisation of serogroup C strains of Neisseria meningitidis that are resistant to killing by sera from individuals immunised with the serogroup C conjugate vaccine, abstr. P65. Eighth Meet. Eur. Monitoring Group Meningococci, Dublin, Ireland.
24. van den Dobbelsteen, G., H. van Dtjken, H. Hamstra, R. Ummels, L. van Alphen, and P. van der Ley. 2004. From HexaMen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine, abstr. P153. Fourteenth Int. Pathog. Neisseria Conf., Milwaukee, WI.
25. van der Ley, P., and J. T. Poolman. 1992. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect. Immun. 60:3156-3161.
26. Vermont, C. L., H. H. van Dijken, A. J. Kuipers, C. J. van Limpt, W. C. Keijzers, A. van der Ende, R. de Groot, L. van Alphen, and G. P. van den Dobbelsteen. 2003. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine. Infect. Immun. 71:1650-1655.
27. Wedege, E., E. A. Høiby, E. Rosenqvist, and G. Bjune. 1998. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect. Immun. 66:3223-3231.
28. Wyle, F. A., M. S. Artenstein, B. L. Brandt, E. C. Tramont, D. L. Kasper, P. L. Altieri, S. L. Berman, and J. P. Lowenthal. 1972. Immunological response of man to group B meningococcal polysaccharide antigens. J. Infect. Dis. 126:514-522.
29. Yamasaki, R., W. Nasholds, H. Schneider, and M. A. Apicella. 1991. Epitope expression and partial structural characterization of F62 lipooligosaccharide (LOS) of Neisseria gonorrhoeae: IgM monoclonal antibodies (3F11 and 1-1-M) recognize nonreducing termini of the LOS components. Mol. Immunol. 28:1233-1242.